AMG 151 ( ARRY‐403 ), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes
Authors:
- 5 October 2015
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (2) , 191-195
Abstract
Phase I studies have shown that AMG 151 activates glucokinase, a key enzyme in glucose homeostasis. The present randomized, placebo‐controlled phase IIa study evaluated the dose–effect relationship of the glucokinase activator AMG 151 relative to placebo on fasting plasma glucose ( FPG ) in 236 patients (33–35 patients per arm) with type 2 diabetes treated with metformin. Patients received oral AMG 151 at 50, 100 or 200 mg twice daily, AMG 151 at 100, 200 or 400 mg once daily or matching placebo for 28 days. A significant linear dose–effect trend was observed with the twice‐daily regimen (p = 0.004) for change in FPG to day 28. No trend was observed with the once‐daily regimen. A higher incidence of hypoglycaemia and hypertriglyceridaemia was observed with AMG 151 administration. AMG 151 significantly reduced FPG when administered twice daily but not when administered once daily in patients with type 2 diabetes treated with metformin.Keywords
Funding Information
- Amgen
This publication has 8 references indexed in Scilit:
- Two dose‐ranging studies with PF ‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetesDiabetes, Obesity and Metabolism, 2015
- Utilizing Physiologically Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development for a Compound with pH-Dependent SolubilityJournal of Pharmaceutical Sciences, 2015
- Dose‐ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metforminDiabetes, Obesity and Metabolism, 2013
- GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?Trends in Pharmacological Sciences, 2013
- Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 DiabetesDiabetes Care, 2011
- Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemiaHuman Mutation, 2009
- Defining and Reporting Hypoglycemia in DiabetesDiabetes Care, 2005
- Structural Basis for Allosteric Regulation of the Monomeric Allosteric Enzyme Human GlucokinaseStructure, 2004